AIM: To evaluate the efficacy of intravitreal injection with Ranibizumab combined with sub-Tenon injection with Triamcinolone acetonide(TA)for macular edema(ME)due to central retinal venous occlusions(CRVO).

METHODS:Forty-six patients(46 eyes)were diagnosed ischemic CRVO with significant macular edema by fundus fluorescence-angiography(FFA)and optical coherence tomography(OCT). All the patients had panretinal photocoagulation(PRP), a week after the four times therapies. Twenty-three patients(23 eyes)in group A were randomly chosen to receive intravitreal injection with ranibizumab(IVR), another 23 patients(23 eyes)in group B to treat with both IVR and sub-Tenon injection with TA(PSTT). There was no significant difference on macular edema and best corrected visual activity(BCVA)between the two groups. The changes in BCVA and central macular thickness(CMT)before and 1wk; 1, 3, 6mo after treatments were analyzed.

RESULTS: One week after the treatment: the BCVA increased while the CMT decreased compared with that of pretreatment in groups A and B(P<0.05). BCVA and CMT changes between two groups were statistically significant differences(P<0.05). One month and three months after the treatment: the BCVA increased while the CMT decreased compared with that of pretreatment in group A and B(P<0.05), the difference was significant between two groups(P<0.05). Six month after the treatment: the BCVA increased while the CMT decreased compared with that of pretreatment in groups A and B. Compare BCVA difference between the groups was statistically significant change(P<0.05), CMT difference was not statistically significant(P>0.05).

CONCLUSION: Not only IVR can decrease ME caused by CRVO and increase the BCVA, but also IVR combined with PSTT can. But combined therapies can be more rapidly and have more positive effect on decreasing the ME and protecting the visual function.